Biosenta Inc.
ZRO.CN · CNQ
9/30/2024 | 9/30/2023 | 9/30/2022 | 9/30/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.01 | 0.15 | -0.04 |
| FCF Yield | -30.09% | -5.16% | -5.92% | -7.13% |
| EV / EBITDA | -7.46 | -2.66 | -6.95 | -4.66 |
| Quality | ||||
| ROIC | 50.99% | 67.50% | 43.58% | 82.72% |
| Gross Margin | 60.55% | 40.98% | 63.25% | 58.96% |
| Cash Conversion Ratio | 0.35 | 0.09 | 0.35 | 0.33 |
| Growth | ||||
| Revenue 3-Year CAGR | 6.21% | -81.63% | -9.05% | – |
| Free Cash Flow Growth | -37.61% | -12.27% | 24.97% | -110.27% |
| Safety | ||||
| Net Debt / EBITDA | -5.09 | -0.90 | -0.05 | -0.02 |
| Interest Coverage | -1.04 | -23.46 | -5.42 | -197.06 |
| Efficiency | ||||
| Inventory Turnover | 0.01 | 0.02 | 0.01 | 0.89 |
| Cash Conversion Cycle | -848,572.02 | -696,373.67 | -564,484.73 | -2,625.55 |